

EQA round: IDDM2/23 - Type 1 Autoimmune Diabetes

Deadline: 20.10.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessedN_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
(472) anti-GAD		29			29	28	97	
Sample A		29			29	29	100	
(2) EIA methods	CVP >>>	22	76	Positive				
(3) RIA, IRMA	CVP >>>	2	6,9	Positive				
(4) Luminiscence	CVP >>>	1	3,4	Positive				
(99) Another measurement principle	CVP >>>	4	14	Positive				
Sample B		29			29	28	97	
(2) EIA methods	CVP >>>	22	76	Positive				
(3) RIA, IRMA		1	3,4	Negative				
	CVP >>>	1	3,4	Positive				
(4) Luminiscence	CVP >>>	1	3,4	Positive				
(99) Another measurement principle	CVP >>>	4	14	Positive				
(474) anti-IA-2		26			26	25	96	
Sample A		26			26	26	100	
(2) EIA methods	CVP >>>	20	77	Positive				
(3) RIA, IRMA	CVP >>>	1	3,8	Positive				
(4) Luminiscence	CVP >>>	1	3,8	Positive				
(99) Another measurement principle	CVP >>>	4	15	Positive				
Sample B		26			26	25	96	
(2) EIA methods	CVP >>>	19	73	Negative				
		1	3,8	Positive				
(3) RIA, IRMA	CVP >>>	1	3,8	Negative				
(4) Luminiscence	CVP >>>	1	3,8	Negative				
(99) Another measurement principle	CVP >>>	4	15	Negative				